eMed CEO Linda Yaccarino on joining the health startup, thoughts on Elon Musk

Watch on YouTube ↗  |  January 12, 2026 at 12:33  |  8:07  |  CNBC
Speakers
Linda Yaccarino — CEO, eMed

Summary

Linda Yaccarino, CEO of eMed and former X CEO, discusses her move to the health startup and its GLP-1 medication program. She explains how eMed aims to improve adherence and lower healthcare costs, highlights Tom Brady's role as Chief Wellness Officer, and describes GLP-1s as a transformative health intervention. She also reflects on her tenure at X and Elon Musk's controversial comments to advertisers.

  • Linda Yaccarino is now CEO of private health startup eMed.
  • eMed offers a GLP-1 program with labs, qualification checks, and weekly accountability.
  • Tom Brady joins eMed as Chief Wellness Officer to support long-term wellness discipline.
  • Yaccarino argues GLP-1 medications can reduce costs by improving adherence and outcomes.
  • She sees GLP-1 use expanding into kidney, liver, heart, mental health, menopause, and addiction.
  • Employers and strategic partners like AON are framed as key channels for scaling GLP-1 adoption.
  • She cites Goldman Sachs' estimate that GLP-1s could add $120 billion to the economy this year.
  • She reflects on Elon Musk's advertiser comments and describes transformation as messy.
Ideas
Linda Yaccarino CEO, eMed 2:26
GLP-1 drugs are transformative and expanding.
GLP-1 medications are a transformative health intervention addressing chronic disease and obesity, and they can lower escalating healthcare costs if patients adhere to structured programs. Their use is expanding beyond diabetes and weight loss into kidney, liver, heart, mental health, menopause, and addiction, and employer channels are key to scaling adoption.
GLP-1 medications HIGH
Up Next
4:14
Jonathan Kanter on Powell criminal probe: The bar for convicting somebody for a crime is very high
CNBC · Jan 12
48:36
India's Modi Hosts Germany's Merz as Trump Threatens Iran | The Pulse 1/12/2026
Bloomberg Markets · Jan 12
1:36:06
Fed Served with Grand Jury Subpoenas, Heineken CEO Steps Down | The Opening Trade 1/12/2026
Bloomberg Markets · Jan 12
3:32
Pres. Trump calls for credit card rate cap: Here's what to know
CNBC · Jan 12
9:19
Fed Chair Powell says he faces criminal probe over Fed HQ renovations
CNBC · Jan 12

This CNBC video, published January 12, 2026, features Linda Yaccarino discussing GLP-1 medications. 1 trade idea extracted by AI with direction and confidence scoring.

Speakers: Linda Yaccarino  · Tickers: GLP-1 medications